HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT01559272

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia

Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Little Rock and 35 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study clarity

Study information

Study start dateStarted: February 21, 2008
Recruitment status
Completed
Enrollment listed in the registry
328
Sponsor
Janssen Research & Development, LLC
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States, Belgium, Bulgaria, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT01559272
Official title
Show the full official title

A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Little Rock, United States · Cerritos, United States · Garden Grove, United States

33 more locations
  • Glendale, United States
  • National City, United States
  • Paramount, United States
  • Atlanta, United States
  • Philadelphia, United States
  • Austin, United States
  • DeSoto, United States
  • Aalst, Belgium
  • Diest, Belgium
  • Burgas, Bulgaria
  • Zagreb, Croatia
  • Beer Yaakov, Israel
  • Hod HaSharon, Israel
  • Ramat Gan, Israel
  • Johor Bahru, Malaysia
  • Kuala Lumpur, Malaysia
  • Perak, Malaysia
  • Bratislava, Slovakia
  • Michalovce, Slovakia
  • Rimavská Sobota, Slovakia
  • Bloemfontein, South Africa
  • Cape Town, South Africa
  • Incheon, South Korea
  • Jeonju, South Korea
  • Seoul, South Korea
  • Badajoz, Spain
  • Badalona, Spain
  • Barcelona, Spain
  • Seville, Spain
  • Zamora, Spain
  • Hualien City, Taiwan
  • Taipei, Taiwan
  • Taoyuan, Taiwan
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Janssen Research & Development, LLC.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone IR (Period 1), Paliperidone palmitate F015 (Panel A: treatment group 1), Paliperidone palmitate F015 (Panel A: treatment group 2), Paliperidone palmitate F015 (Panel B: treatment group 1), Paliperidone palmitate F015 (Panel B: treatment group 2), Paliperidone palmitate F015 (Panel B: treatment group 3), Paliperidone palmitate F015 (Panel B: treatment group 4), Paliperidone palmitate F015 (Panel B: treatment group 5), Paliperidone palmitate F016, Paliperidone palmitate F015 (Panel D: treatment group 1), Paliperidone palmitate F015 (Panel D: treatment group 2), Paliperidone palmitate F015 (Panel D: treatment group 3) and Paliperidone palmitate F015 (Panel D: treatment group 4).

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies